Involvement of uric acid transporter in increased renal clearance of the xanthine oxidase inhibitor oxypurinol induced by a uricosuric agent, benzbromarone.

Involvement of uric acid transporter in increased renal clearance of the xanthine oxidase inhibitor oxypurinol induced by a uricosuric agent, benzbromarone.

Item
http://www.wikidata.org/entity/Q34447431
Lesinurad in combination with allopurinol: results of a phase 2, randomised, double-blind study in patients with gout with an inadequate response to allopurinolUrate Handling in the Human BodyGenetic variation in drug transporters in ethnic populations.SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuriaImpaired response or insufficient dosage? Examining the potential causes of "inadequate response" to allopurinol in the treatment of goutEffect of hypouricaemic and hyperuricaemic drugs on the renal urate efflux transporter, multidrug resistance protein 4.High-throughput screening of a collection of known pharmacologically active small compounds for identification of Candida albicans biofilm inhibitorsGenome-wide association study identifies ABCG2 (BCRP) as an allopurinol transporter and a determinant of drug response.The pharmacokinetics of oxypurinol in people with gout.Semi-mechanistic kidney model incorporating physiologically-relevant fluid reabsorption and transporter-mediated renal reabsorption: pharmacokinetics of γ-hydroxybutyric acid and L-lactate in ratsLesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney.Uricosuric targets of tranilast.Lesinurad, a Selective Uric Acid Reabsorption Inhibitor, in Combination With Febuxostat in Patients With Tophaceous Gout: Findings of a Phase III Clinical Trial.Immunohistochemical studies of organic anion transporters and urate transporter 1 expression in human salivary gland.Mendelian randomization analysis associates increased serum urate, due to genetic variation in uric acid transporters, with improved renal function.Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with allopurinol in adults with gout: a phase IIa, open-label study.Functional comparison of anoctamin 1 antagonists on human uterine smooth muscle contractility and excitability.
P2860

Involvement of uric acid transporter in increased renal clearance of the xanthine oxidase inhibitor oxypurinol induced by a uricosuric agent, benzbromarone.

Item
http://www.wikidata.org/entity/Q34447431
description
2005 nî lūn-bûn
@nan
2005 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Involvement of uric acid trans ...... icosuric agent, benzbromarone.
@ast
Involvement of uric acid trans ...... icosuric agent, benzbromarone.
@en
Involvement of uric acid trans ...... icosuric agent, benzbromarone.
@nl
type
label
Involvement of uric acid trans ...... icosuric agent, benzbromarone.
@ast
Involvement of uric acid trans ...... icosuric agent, benzbromarone.
@en
Involvement of uric acid trans ...... icosuric agent, benzbromarone.
@nl
prefLabel
Involvement of uric acid trans ...... icosuric agent, benzbromarone.
@ast
Involvement of uric acid trans ...... icosuric agent, benzbromarone.
@en
Involvement of uric acid trans ...... icosuric agent, benzbromarone.
@nl
P1433
P1476
P2093
P304
P31
P356
P433
P478
P50
P577
P698
P921
P356
P1433
P1476
Involvement of uric acid trans ...... ricosuric agent, benzbromarone
@en
P2093
P304
P31
P356
P433
P478
P50
P577
P698
P921